Insider · CIK 0001527710
James Patrick Tursi
Files at MTVA (NeuroBo Pharmaceuticals, Inc.). First filing -, latest -.
In brief
James Patrick Tursi files SEC Form 4 as director at MTVA (NeuroBo Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Patrick Tursi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +17,186 | $0.00 | $0 | 20,568 | Jun 8, 2026 |
| Jun 30, 2025 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +28,147 | $0.00 | $0 | 37,219 | Jul 1, 2025 |
| Dec 1, 2023 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 25,000 | Dec 4, 2023 |
| Dec 1, 2023 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +7,157 | $0.00 | $0 | 32,157 | Dec 4, 2023 |
Questions about James Patrick Tursi
Answered from the filings on this page, as of the latest one.
Is James Patrick Tursi buying or selling?
James Patrick Tursi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Patrick Tursi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Patrick Tursi has 0.
Where does James Patrick Tursi file Form 4?
James Patrick Tursi has filed Form 4 at MTVA (NeuroBo Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.